Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study
M. Reindl et al., Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study, BRAIN, 122, 1999, pp. 2047-2056
In experimental animal models of multiple sclerosis demyelinating antibody
responses are directed against the myelin oligodendrocyte glycoprotein (MOG
). We have investigated whether a similar antibody response is also present
in multiple sclerosis patients. Using the recombinant human extracellular
immunoglobulin domain of MOG (MOG-Ig) we have screened the sera and CSFs of
130 multiple sclerosis patients, 32 patients with other inflammatory neuro
logical diseases (OIND), 30 patients with other non-inflammatory neurologic
al diseases (ONND) and 10 patients with rheumatoid arthritis. We report tha
t 38 % of multiple sclerosis patients are seropositive for IgG antibodies t
o MOG-Ig compared with 28 % seropositive for anti-myelin basic protein (MBP
). In contrast, OIND are characterized by similar frequencies of serum IgG
antibody responses to MOG-Ig (53 %) and MBP (47 %), whereas serum IgG respo
nses to MOG-Ig are rare in ONND (3 %) and rheumatoid arthritis (10 %). Anti
-MBP IgG antibodies, however, are a frequent finding in ONND (23 %) and rhe
umatoid arthritis (60 %). Our results provide clear evidence that anti-MOG-
Ig antibodies are common in CNS inflammation. However, in OIND these antibo
dy responses are transient, whereas they persist in multiple sclerosis. We
demonstrate that the serum anti-MOG-Ig response is already established in e
arly multiple sclerosis (multiple sclerosis-R0; 36 %). In later multiple sc
lerosis stages frequencies and titres are comparable with early multiple sc
lerosis. In contrast, the frequency of anti-MBP antibodies is low in multip
le sclerosis-R0 (12 %) and increases during disease progression in relapsin
g-remitting (32 %) and chronic progressive multiple sclerosis (40 %), thus
suggesting that anti-MBP responses accumulate over time. Finally we provide
evidence for intrathecal synthesis of IgG antibodies to MOG-Ig in multiple
sclerosis.